MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
Journal Article

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

2007
Request Book From Autostore and Choose the Collection Method
Overview
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease. The combination of gemcitabine and carboplatin was therefore investigated as an anthracycline- and taxane-free treatment option. Patients and Methods: MBC patients previously treated with chemotherapy were enrolled in a multicenter phase II study. Treatment consisted of gemcitabine (1,000 mg/m 2 i.v. on days 1 and 8) and carboplatin (AUC 4 i.v. on day 1) applied every 3 weeks. Results: Thirty-nine patients were recruited, and a total of 207 treatment cycles were applied with a median of 5 cycles per patient. One complete response and 11 partial responses were observed for an overall response rate of 31% (95% CI: 17–48%). Twelve patients (31%) had stable disease. Median time to progression was 5.3 months (95% CI: 2.6–6.7 months) and median overall survival from start of treatment was 13.2 months (95% CI: 8.7–16.7 months). Grade 3/4 hematological toxicity included leukopenia (59%/5%), thrombocytopenia (26%/23%) and anemia (10%/0%). Nonhematological toxicity was rarely severe. Conclusion: Combination chemotherapy with gemcitabine and carboplatin is an effective and generally well-tolerated treatment option for intensively pretreated patients with MBC. Due to a considerable incidence of severe thrombocytopenia it would be reasonable to consider starting gemcitabine at the lower dose level of 800 mg/m 2 .